Table 4.
Analyses of pooled hazard ratios for OS outcomes by subgroup in clinical practice.
| Variables | Study, N (%) | Number of patients (LM/non-LM) | Pooled HR (95%CI) | p value of heterogeneity |
|---|---|---|---|---|
| Overall | 14 (100) | 826/3427 | 1.22 (1.17,1.27) | |
| Line of therapy | ||||
| First-line | 4 (29) | 212/898 | 1.21 (1.11,1.31) | |
| Second- or later line | 4 (29) | 349/1293 | 1.25 (1.17,1.32) | p=0.33 |
| un-selected | 6 (42) | 265/1236 | 1.16 (1.07,1.26) | |
| Country | ||||
| Asian | 6 (42) | 318/1751 | 1.28 (1.07,1.53) | p=0.79 |
| Western | 8 (58) | 508/1676 | 1.21 (1.16,1.27) | |
LMs, liver metastases; OS, overall survival; HR, hazard ratio; CI, confidence interval.